nach oben

Reactions Weekly

Erschienen in:

01.10.2019 | Case report

Hydrochlorothiazide/immunostimulants/quinapril

Lichen planus rash: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In case reports received from the Centre for Adverse Reactions Monitoring (CARM) database of New Zealand Medicines and Medical Devices Safety Authority, a 67-year-old woman (CARM ID: 125605) was described, who developed lichen planus rash following vaccination with varicella zoster virus vaccine live [Zostavax; zoster vaccine] and influenza vaccine. A punch biopsy confirmed lichen planus rash. Additionally, she was receiving hydrochlorothiazide and quinapril, which contributed to the lichen planus rash [dosages, routes, duration of treatments to reaction onsets and outcomes not stated; not all indication stated]. …

New Zealand Medicines and Medical Devices Safety Authority. Possible risk of lichen planus or lichenoid drug eruption with zoster (shingles) vaccine or influenza vaccine Internet Document : 25 Sep 2019. Available from: URL: https://www.medsafe.govt.nz/safety/EWS/2018/ZosterAndInfluenza.asp - New Zealand

Titel: Hydrochlorothiazide/immunostimulants/quinapril
Lichen planus rash: case report
Publikationsdatum: 01.10.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-68939-x

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Hydrochlorothiazide/immunostimulants/quinapril

Lichen planus rash: case report

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Norepinephrine

Dexamethasone/rituximab

Propofol/sevoflurane

Immune-globulin/natalizumab

Lanthanum carbonate

Povidone iodine/propofol/soya oil emulsion